List view / Grid view
16 January 2015 | By GlobalData
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData...
14 January 2015 | By GlobalData
Denmark’s pharmaceutical market will decline in value from $3.5 billion in 2013 to $3 billion by 2020, with price-cap agreements and high tax rates on pharmaceutical products two of the largest barriers to growth, according to research and consulting firm GlobalData...
14 January 2015 | By GlobalData
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData...
7 January 2015 | By GlobalData
The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to research and consulting firm GlobalData...
17 December 2014 | By GlobalData
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData...
11 December 2014 | By GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData...
4 December 2014 | By GlobalData
The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.
3 December 2014 | By GlobalData
The Age-related Macular Degeneration treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm GlobalData.
21 November 2014 | By GlobalData
The vote against the recommendation that the US Food and Drug Administration (FDA) approves Novartis’ panobinostat (Farydak) for use in relapsed/refractory multiple myeloma by the Oncologic Drugs Advisory Committee (ODAC) signals that a US marketing authorization is unlikely to be granted, according to an analyst with research and consulting firm…
19 November 2014 | By GlobalData
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData...
18 November 2014 | By Actavis
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Actavis has agreed to purchase Allergan for around $66 billion, in a deal which draws to an end Valeant’s lengthy wrangle to acquire the Botox manufacturer..."
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
31 October 2014 | By GlobalData
While the collaboration between Sanofi Pasteur (Sanofi) and Immune Design to develop a genital herpes vaccine presents a strong scientific foundation and difficult-to-match financial clout, the partnership needs to create a product with better clinical performance to compete with more advanced pipeline vaccine candidates, says an analyst with research and…
24 October 2014 | By GlobalData
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
